This morning Lund-based drug developer RhoVac released its year-end report. CEO Anders Månsson visited BioStock’s studio to tell us more about the company’s challenges and achievements during 2020 as well as the company’s development plan going forward. Månsson points out that the company has entered 2021 on solid ground and with strong finances, and is now continuing development and recruitment for the ongoing phase IIb study.
Watch the interview with CEO Anders Månsson below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.